Top 8 Idiopathic Pulmonary Fibrosis startups

Oct 10, 2024 | By Jason Kwon

These startups develop new technologies to diagnose and treat Idiopathic Pulmonary Fibrosis such as genetic testing, pulmonary function tests, biomarkers AI analysis, artificial intelligence for imaging analysis, digital health platforms, antifibrotic therapies.
1
Country: Hong Kong | Funding: $401.3M
Insilico aims to apply artificial intelligence to extend human productive longevity and transform the pharmaceutical industry.
2
Country: USA | Funding: $295.5M
Endeavor is a clinical-stage company developing a best-in-class Hedgehog inhibitor for Idiopathic Pulmonary Fibrosis.
3
Country: USA | Funding: $272.5M
Avalyn Pharma is a biopharma company developing therapies for the treatment of idiopathic pulmonary fibrosis and other respiratory diseases.
4
Country: USA | Funding: $145.6M
Mediar is a pre-clinical stage biotechnology company developing therapeutics for the treatment of fibrosis.
5
Country: USA | Funding: $22.3M
Aqualung Therapeutics is developing a novel, anti-inflammatory monoclonal antibody strategy to treat serious unchecked inflammation.
6
Country: Germany | Funding: €4.7M
VisionHealth supports patients with chronic lung diseases who are dependent on their inhaler.
7
Country: USA
Empower clinicians to make the best decisions
8
Country: Germany
Boehringer Ingelheim is a group of pharmaceutical companies that focuses on prescription medicines and animal health.
Editor: Jason Kwon
Jason Kwon is a senior editor for MedicalStartups. He has previously covered the pharmaceutical and medical research industries for FDAnews and worked as a head of marketing for medical startup Sonic Therapeutics. Before that, he co-founded a startup consulting business for emerging entrepreneurial hubs in Asia. Jason graduated from St. Bonaventure University’s journalism school. In his free time, Jason enjoys yoga, watching movie trailers, traveling to places where he can't get cell service. You can contact Jason at jaskwon(at)medicalstartups(dot)com